Hatch-Waxman litigation over Lamictal
GlaxoSmithKline Plc will defend the patent on its best-selling anti-epileptic drug Lamictal in DNJ on Jan. 18 in a Hatch-Waxman infringement suit against Teva. Lamictal, which is also used to treat bipolar depression, represents about 4 percent of GSK drug sales. Worldwide Lamictal revenues were $928 million in the first 9 month of 2004, with the US share about 60%.
The main U.S. patent on Lamictal expires in mid-2008.